Robert Michael Dudley - 27 May 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol
RNAZ
Transactions as of
27 May 2022
Net transactions value
+$55,383
Form type
4
Filing time
01 Jun 2022, 16:01:27 UTC
Previous filing
03 Feb 2022
Next filing
16 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAZ Common Stock Purchase $51,643 +28,000 +3.3% $1.84 871,114 27 May 2022 Direct
transaction RNAZ Common Stock Purchase $3,740 +2,000 +0.23% $1.87 873,114 31 May 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.